India Presses Chinese API Firms Over Quality Concerns

 
• By Ying Huang and Anju Ghangurde

Tougher regulatory scrutiny by India amid its massive reliance on such raw materials from China is anticipated, but the current Indian inspection action is just 'normal regulatory duties,' a Shanghai-based regulatory officer said.

Pills
CHINESE API FIRMS ARE UNDER SCRUTINY BY THE INDIAN REGULATOR

More from Drug Safety

More from Pink Sheet